STOCK TITAN

Cue Biopharma (CUE) awards RSUs and stock options to CMO Borie

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Cue Biopharma, Inc. granted its Chief Medical Officer and Head of Research & Development, Dominique Christian Borie, 31,500 restricted stock units (RSUs) and stock options for 63,000 shares of common stock. The options carry an exercise price of $30.9200 per share and expire on July 13, 2036.

The RSUs and options each vest in equal quarterly installments over four years starting July 13, 2026, contingent on Borie’s continued service with the company. Following these grants, Borie holds 31,500 common shares and options on 63,000 shares directly.

Positive

  • None.

Negative

  • None.
Insider Borie Dominique Christian
Role Chief Medical Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 63,000 $0.00 --
Grant/Award Common Stock 31,500 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 63,000 shares (Direct); Common Stock — 31,500 shares (Direct)
Footnotes (1)
  1. Represents the grant of restricted stock units ("RSUs"). The shares subject to the RSU vest in equal quarterly installments over four years from July 13, 2026, subject to the reporting person's continued service with the issuer through each vest date. The stock option becomes exercisable in equal quarterly installments over four years from July 13, 2026, subject to the reporting person's continued service with the issuer through each vest date.
RSUs granted 31,500 shares Restricted stock units granted to the Chief Medical Officer on July 13, 2026
Stock options granted 63,000 shares Options on Cue Biopharma common stock granted July 13, 2026
Option exercise price $30.9200 per share Exercise price for the 63,000 stock options granted to Borie
Option expiration date 2036-07-13 Expiration date for the stock options granted to Borie
Vesting schedule Four years, quarterly installments RSUs and options vest in equal quarterly installments over four years from July 13, 2026
restricted stock units financial
"Represents the grant of restricted stock units ("RSUs"). The shares subject to the RSU vest"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Represents the grant of restricted stock units ("RSUs"). The shares subject to the RSU vest"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
stock option financial
"The stock option becomes exercisable in equal quarterly installments over four years"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercisable financial
"The stock option becomes exercisable in equal quarterly installments over four years"
vest financial
"The shares subject to the RSU vest in equal quarterly installments over four years"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity awards did Cue Biopharma (CUE) grant to Dominique Christian Borie?

Cue Biopharma granted Dominique Christian Borie 31,500 RSUs and stock options for 63,000 common shares. The options have a $30.9200 exercise price and expire on July 13, 2036, forming part of his executive equity compensation package.

How do the Cue Biopharma (CUE) RSUs granted to Borie vest?

The 31,500 RSUs vest in equal quarterly installments over four years starting July 13, 2026. Each installment is contingent on Borie’s continued service with Cue Biopharma through the applicable vesting date.

What are the key terms of Borie’s Cue Biopharma (CUE) stock options?

Borie received options for 63,000 shares of Cue Biopharma common stock at a $30.9200 exercise price, expiring on July 13, 2036. The options become exercisable in equal quarterly installments over four years from July 13, 2026.

How many Cue Biopharma (CUE) shares and options does Borie hold after these grants?

After these awards, Borie directly holds 31,500 shares of common stock and stock options for 63,000 shares. These positions reflect newly granted RSUs and options subject to four-year quarterly vesting schedules.

Are Borie’s Cue Biopharma (CUE) equity awards tied to continued employment?

Yes. Both the 31,500 RSUs and the options on 63,000 shares vest or become exercisable only if Borie continues serving Cue Biopharma through each quarterly vesting date over the four-year schedule beginning July 13, 2026.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Borie Dominique Christian

(Last)(First)(Middle)
C/O CUE BIOPHARMA, INC.
40 GUEST STREET

(Street)
BOSTON MASSACHUSETTS 02135

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)XOther (specify below)
Chief Medical OfficerHead of Research & Development
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/13/2026A31,500(1)A$031,500D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$30.9207/13/2026A63,000 (2)07/13/2036Common Stock63,000$063,000D
Explanation of Responses:
1. Represents the grant of restricted stock units ("RSUs"). The shares subject to the RSU vest in equal quarterly installments over four years from July 13, 2026, subject to the reporting person's continued service with the issuer through each vest date.
2. The stock option becomes exercisable in equal quarterly installments over four years from July 13, 2026, subject to the reporting person's continued service with the issuer through each vest date.
/s/ Dominique Borie07/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)